Compare FVCB & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | AMRN |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.0M | 304.7M |
| IPO Year | 2018 | 1998 |
| Metric | FVCB | AMRN |
|---|---|---|
| Price | $16.26 | $14.12 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 1 | 1 |
| Target Price | ★ $18.00 | $12.00 |
| AVG Volume (30 Days) | ★ 178.5K | 50.3K |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | 47.56 | ★ 55.00 |
| EPS | ★ 0.35 | N/A |
| Revenue | $1,781,000.00 | ★ $181,104,000.00 |
| Revenue This Year | $13.83 | N/A |
| Revenue Next Year | $7.45 | $1.26 |
| P/E Ratio | $45.80 | ★ N/A |
| Revenue Growth | 13.87 | ★ 39.22 |
| 52 Week Low | $11.13 | $11.67 |
| 52 Week High | $16.35 | $20.90 |
| Indicator | FVCB | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 44.79 |
| Support Level | $15.28 | $13.46 |
| Resistance Level | $16.26 | $14.49 |
| Average True Range (ATR) | 0.32 | 0.52 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 90.87 | 37.86 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.